Brown Brothers Harriman & Co’s Lifecore Biomedical LFCR Stock Holding History

Brown Brothers Harriman & Co’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-900	Closed	-$11K	–	1174
2019 Q1	$11K	Hold	900	–	–	﹤0.01%	827
2018 Q4	$11K	Hold	900	–	–	﹤0.01%	684
2018 Q3	$13K	Hold	900	–	–	﹤0.01%	661
2018 Q2	$13K	Hold	900	–	–	﹤0.01%	635
2018 Q1	$12K	Buy	+900	New	+$11.8K	﹤0.01%	646

Other funds holding LFCR

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Brown Brothers Harriman & Co's LFCR Position: Q2 2019 in Review

Brown Brothers Harriman & Co sold out of Lifecore Biomedical (LFCR) in Q2 2019, closing a stake of 900 shares — an estimated $11K sold.

Brown Brothers Harriman & Co first reported a position in LFCR in Q1 2018 and held it in 5 quarters. The position peaked at $13K in Q3 2018. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2019.

Brown Brothers Harriman & Co reported no remaining Lifecore Biomedical position as of Q2 2019 after selling out during the quarter.
Brown Brothers Harriman & Co sold 900 Lifecore Biomedical shares in Q2 2019, an estimated $11K.
Brown Brothers Harriman & Co first reported a position in Lifecore Biomedical in Q1 2018 and held it in 5 quarters.
Brown Brothers Harriman & Co's Lifecore Biomedical position peaked at $13K in Q3 2018.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2019.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2019, filed 14 Aug 2019.